Sandoz’s Hyrimoz (adalimumab) Receives EU Approval for Autoimmune Disorders

Shots:

• The approval is based on non-inferiority data assessing Hyrimoz vs reference biologic in patients with rheumatoid arthritis, plaque psoriasis, Crohn’s disease, uveitis and ulcerative colitis
• The study demonstrated in meeting al 1EPs and resulted bioequivalence in terms of safety, efficacy, PK, immunogenicity in patients with moderate to severe chronic plaque-type psoriasis
• Hyrimoz (adalimumab) is an inhibitor of tumor necrosis factor (TNF) indicated for rheumatoid arthritis, plaque psoriasis, Crohn’s disease and ulcerative colitis-causing inflammation and tissue destruction

Click here read full press release/ article | Ref: Sandoz | Image: Twitter